Update your location to show providers, locations, and services closest to you.
I am a Professor and Medical Director of the Diabetes Institute and Director of the Clinical Research Center within the CTSI at the University of Florida, Gainesville. I served as President of Science and Medicine of the American Diabetes Association in 2016. I have been involved in Type 1 diabetes research since the mid 1980’s and have published over 400 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 diabetes. I am the Principal Investigator (PI) on several NIH awards, and I am the PI of the University of Florida Clinical Center participating in the NIH-funded TrialNet (a founding member of the DPT-1 in 1994). I am co-PI on a Program Project Grant seeking to understand the immunopathogenesis of Type 1 diabetes, and also serve as PI for the NIH-funded international newborn genetic screening (TEDDY) program in North Central Florida. I am the PI on the NIH-funded Human Islet Research Network (HIRN) Grant evaluating novel markers and mechanisms of beta cell destruction, as well as, the PI of the University of Florida site participating in the Type 1 Diabetes Exchange. I have served in numerous capacities (Committees, Study Sections) for the American Diabetes Association, JDRF and NIH. I am the recipient of multiple awards including the Mary Tyler Moore and S Robert Levine JDRF Excellence in Clinical Research Award, the 2009 Cure Award from the American Diabetes Association, the 2010 Public Policy Leadership Award, the prestigious Banting Medal for service from the American Diabetes Association, the ISPAD Prize for achievement (the highest honor of the International Society for Pediatric and Adolescent Diabetes) both in 2016 and, more recently in 2021, the distinguished George Eisenbarth Award from the JDRF for outstanding research advances toward the prevention of Type 1 diabetes. In 2022 I was elected into the prestigious Academy of Science, Engineering and Medicine of Florida (ASEMFL).
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible…
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
June 14, 2022
Related video: UF Health Shands Children’s Hospital ranked No. 1 in Florida University of Florida Health Shands Children’s Hospital continued its remarkable…
College of Medicine, UF Health Shands Children's Hospital, +2 more
June 22, 2021
An internationally recognized physician who performed more than 100 lung transplants has joined the University of Florida Health Shands Children’s Hospital to…
Department of Pediatrics, +3 more
